General Statement of Disclosure:

CONSULTING FEES/HONORARIA: Regeneron(MODEST), Astra Zeneca(SIGNIFICANT), Boehringer Ingelheim(SIGNIFICANT), Kowa(MODEST), Amgen(SIGNIFICANT), Sanofi(SIGNIFICANT), Pfizer(MODEST), Novo Nordisk(SIGNIFICANT), Novartis Corporation(SIGNIFICANT), Daiichi Sankyo(SIGNIFICANT), Cargene(SIGNIFICANT), Eli Lilly and Company(MODEST), Bayer Healthcare Pharmaceuticals(SIGNIFICANT), SCRIBE(SIGNIFICANT), CRISPR(MODEST), VAXXINITY(MODEST), Abbott Laboratories(MODEST), Silence Therapeutics(SIGNIFICANT), Esperion(SIGNIFICANT), New Amsterdam Pharma(SIGNIFICANT), Emendobio(MODEST), Nodthera(MODEST) EQUITY INTERESTS/STOCK OPTIONS: new Amsterdam Pharma(SIGNIFICANT), PEMI31(MODEST) RESEARCH/RESEARCH GRANTS: Regeneron(SIGNIFICANT), Amgen(SIGNIFICANT), Daiichi Sankyo(SIGNIFICANT), Sanofi(SIGNIFICANT), Ultragenix(SIGNIFICANT)

View Full Disclosure